Business
Adia Med Leads Charge to Standardize Umbilical Cord Stem Cell Use Nationwide, Prepares Presentation for New Head of DHHS and FDA
Winter Park, Florida--(Newsfile Corp. - March 20, 2025) - Adia Med, a division of ADIA Nutrition Inc. (OTC Pink: ADIA), is driving a transformative effort to standardize umbilical cord stem cell use across the United States, prioritizing quality, safety, and accountability. This initiative sets rigorous best practices, mandates third-party verification, and ensures homologous applications, aiming to redefine excellence in regenerative medicine. Adia Med plans to present these pioneering standard
About this update from Adia Nutrition, Inc.
[{"type":"text","content":"Winter Park, Florida--(Newsfile Corp. - March 20, 2025) - Adia Med, a division of ADIA Nutrition Inc. (OTC Pink: ADIA), is driving a transformative effort to standardize umbilical cord stem cell use across the United States, prioritizing quality, safety, and accountability. This initiative sets rigorous best practices, mandates third-party verification, and ensures homologous applications, aiming to redefine excellence in regenerative medicine. Adia Med plans to present these pioneering standards to the new head of the Department of Health and Human Services, and the FDA, advocating for federal alignment to address widespread inconsistencies in stem cell therapies.","length":673,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":312,"height":200,"url":"https://media.zenfs.com/en/newsfile_64/8fddfb814aba762040c05f7e2f1d5b81"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.7yvWOOI8I6m2h_ikWiV2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI2OTtjZj13ZWJw/https://media.zenfs.com/en/newsfile_64/8fddfb814aba762040c05f7e2f1d5b81","width":312,"height":200}}},{"type":"text","content":"Cannot view this image? Visit:https://images.newsfilecorp.com/files/10520/243473_fda.jpg","length":89,"tagName":"p","attribs":{}},{"type":"text","content":"Patients nationwide have long grappled with a troubling issue: many clinics provide low-quality or non-viable—"dead"—stem cells, with no way for recipients to verify potency or quantity. This lack of oversight has eroded trust and limited the promise of regenerative medicine. Adia Med is stepping up to ensure every patient receives live, viable stem cells in the amounts promised, backed by unmatched quality controls.","length":430,"tagName":"p"},{"type":"text","content":""Umbilical cord stem cells could revolutionize healthcare, but only if patients can trust what they're getting," said Larry Powalisz, CEO of Adia Nutrition. "We're crafting a movement for reliability and excellence, and we're taking it to the new head of the Department of Health and Human Services and the FDA to create a national standard that protects patients and lifts the entire industry."","length":427,"tagName":"p"},{"type":"text","content":"A Robust Standardization Framework","length":34,"...